IP Library Patent Application 14711127
Patent Application
App. No. 14/711,127

DIAGNOSTIC BIOMARKERS OF DIABETES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/711,127
Abstract

Methods are disclosed for the identification of gene sets that are differentially expressed in PBMCs of patients diagnosed with a pre-diabetic disease state and overt type II diabetes. 3 gene and 10 gene signatures are shown to accurately predict a diabetic disease state in a patient. The application also described kits for the rapid diagnosis of diabetic disease states in patients at a point of care facility.

Claims (9)

1 - 17 . (canceled)

18 . The method of claim 17 , wherein said determining step is executed by a computer system, said computer system running one or more algorithms selected from the group consisting of Linear combination of gene expression signals, Linear regression model, Logistic regression model, Linear discrimination analysis (LDA) model, The nearest neighbor model and the Prediction Analysis of Microarrays (PAM).

19 . The method of claim 18 , wherein said determining step further comprises an analysis of the patient's metabolic disease profile.

20 . The method of claim 17 , wherein said gene signature further comprises one or more genes selected from the genes listed in TABLES 1 or 6.

21 . The method of claim 17 , wherein said diabetic disease state is a pre-diabetic disease state or a Type 2 Diabetes disease state.

22 . The method of claim 17 , wherein said test sample is a blood sample.

23 . The method of claim 17 , wherein said test sample comprises PBMCs or CD11c+ or CD11b+ or Emr+ or [CD11b+CD11c+] or [Emr+CD11b+] or [Emr+CD11c+] or [Emr+CD11b+CD11c+] cells or CD14+ monocytes.

24 . The method of claim 17 , wherein said measuring step involves real-time PCR, an immunochemical assay or specific oligonucleotide hybridization.

25 - 40 . (canceled)

Assignments (3)
NUNC PRO TUNC ASSIGNMENT Recorded Jan 4, 2019
From: MENARINI SILICON BIOSYSTEMS, INC.
To: MENARINI SILICON BIOSYSTEMS S.P.A.
Reel/Frame 049631/0823 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2017
From: JANSSEN DIAGNOSTICS, LLC
To: MENARINI SILICON BIOSYSTEMS, INC.
Reel/Frame 043602/0240 →
CHANGE OF NAME Recorded Sep 15, 2017
From: VERIDEX, LLC
To: JANSSEN DIAGNOSTICS, LLC
Reel/Frame 043867/0285 →